This content is in French.
Immunotherapy on hold?
31 mars 2025
#ColorectalCancer #Immunotherapy #ICI #XL888
#CombinationTherapy
Colorectal cancer (CRC) is one of the leading causes of cancer-related death worldwide, especially in advanced stages where treatment options become limited. The advent of immunotherapy, particularly immune checkpoint inhibitors (ICIs), has transformed the treatment landscape of several solid tumors. In CRC, these treatments have shown remarkable efficacy in patients with microsatellite instability (MSI) or mismatch repair deficiency (dMMR), leading to prolonged and sometimes durable responses.
Colorectal cancer (CRC) is one of the leading causes of cancer-related death worldwide, especially in advanced stages where treatment options become limited. The advent of immunotherapy, particularly immune checkpoint inhibitors (ICIs), has transformed the treatment landscape of several solid tumors. In CRC, these treatments have shown remarkable efficacy in patients with microsatellite instability (MSI) or mismatch repair deficiency (dMMR), leading to prolonged and sometimes durable responses.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Phillips, M. J., et al. (2025). XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trial. Oncoimmunology, 14(1), 2475620
View the source
